Table 1

Change in disease activity in patients with RA, PsA and AS transitioned from reference infliximab to biosimilar infliximab, SB2

Time periodPatients (n)Mean change (95% CI) in disease activity from baseline
RAM0–644∆DAS-28=0.0 (–0.4 to 0.4)
M0–1240∆DAS-28=0.2 (–0.2 to 0.6)
PsAM0–613∆DAS-28=0.1 (–0.5 to 0.7)
M0–1213∆DAS-28=−0.2 (–0.8 to 0.4)
ASM0–6141∆BASDAI=−0.3 (–0.6 to 0.0)
M0–12135∆BASDAI=0.1 (–0.2 to 0.4)
  • AS, ankylosing spondylitis; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; DAS, Disease Activity Score 28 including 28-joint count; M, Month; PsA, psoriatic arthritis; RA, rheumatoid arthritis.